|
|
|
|
|
|
|
Ascendis Pharma Ads (ASND)
|
|
63.81 -1.2 (-1.85%)
|
04-20 16:00
|
|
Open:
|
64.84
|
Pre. Close:
|
65.01
|
|
High:
|
65.61
|
Low:
|
63.515
|
|
Volume:
|
69,924
|
Market Cap:
|
2650M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
65.75 - 66.145
|
66.145 - 66.439
|
|
Low:
|
62.576 - 63.095
|
63.095 - 63.48
|
|
Close:
|
63.132 - 63.894
|
63.894 - 64.461
|
|
|
|
Technical analysis (as of: 2018-04-20 4:27:34 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 79.72 One year: 93.11
|
|
Support:
|
Support1: 61.79 Support2: 57.80
|
|
Resistance:
|
Resistance1:
68.25 Resistance2: 79.72
|
|
Pivot:
|
62.06
|
|
Moving Averages:
|
MA(5): 64.64  MA(20): 62.58
MA(100): 52.91 MA(250): 38.96
|
|
MACD:
|
MACD(12,26):
0.60 Signal(12,26,9): 0.34
|
|
%K %D:
|
%K(14,3): 66.57 %D(3): 70.09
|
|
RSI:
|
RSI(14): 53.12
|
|
52-Week:
|
High: 69
Low: 21.95 Change(%): 127.6
|
|
Average Vol(K):
|
3-Month: 18152
10-Days 8610
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ASND has closed below upper band by 30.7%. Bollinger Bands are 0.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-13T01:03:46-04:00
Institutional Top Ideas Series: DAFNA Capital Management
2018-03-28T19:50:06-04:00
Ascendis Pharma's (ASND) CEO Jan Mikkelsen on Q4 2017 Results - Earnings Call Transcript
2018-03-28T16:05:39-04:00
Ascendis Pharma reports FY results
2018-03-27T17:35:00-04:00
Notable earnings after Wednesdays close
2018-03-19T07:30:00-04:00
PRO+ Weekly Digest: Focusing On Short Ideas Following The Market Rebound
2018-03-17T08:47:14-04:00
Stocks To Watch: Wake-Up Call For The IPO Market
2018-03-16T10:26:29-04:00
Key events next week - healthcare (continued #1)
2018-02-23T08:00:00-05:00
Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
